Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

This region encodes for the reverse transcriptase and protease enzymes, the targets of current antiretroviral drugs. Specific gene sequences are compared with that of a reference (wild-type ...

DEPUTY Minister for Livestock and Fisheries, Mr Alexander Mnyeti, has urged citizens to report any information regarding ...

The treatment combines MSD’s islatravir, an experimental nucleoside reverse transcriptase inhibitor, with Gilead’s ...

Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...

In a groundbreaking development for HIV prevention, the efficacy and safety of a six-monthly injection containing the antiretroviral drug lenacapavir have been confirmed through two pivotal studies.

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Jefferies analyst Akash Tewari has assigned their bullish stance on ARVN stock, giving a Buy rating yesterday. Akash Tewari’s rating is ...

Patients and clinicians have more choices in antiretroviral agents now than in the early 1990s or even at the beginning of this decade. New agents for previously identified drug targets ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

PhD Defense: Pulling the Strings; Exploiting Metabolic Dependencies in Pediatric Cancer ...

We recently published a list of 8 Best Small-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to ...